Clinical trial · Observational
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
NCT01926990CI-TRIAL-00056291completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| perfusion computed tomography | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Characterization of the relationship between Change in blood flow measured through perfusion CT techniques and Change in tumor size measured through non-investigational CT
- timeFrame
- 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication
Secondary outcomes (5)
- measure
- Characterization of the relationship between change in perfusion CT measurements (eg. Mean transit time) and change in tumor size measured by non-investigational CT
- timeFrame
- 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication
- measure
- Relationship between change in blood flow and tumor response measured on ordinal scale
- timeFrame
- 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication
- measure
- Relationship between change in blood flow at Day 8 and change in tumor size measured on continuous scale at Week 12 and tumor response measured on ordinal scale at Week 12
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suspected or biopsy-proven renal cell carcinoma * Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, nivolumab alone or in combination with an investigational agent * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * Serum creatinine greater than or equal to 1.7 mg/dL * Severe allergy to contrast agent * Any contraindication for undergoing a CT scan * Pregnancy or unwillingness to use preventative measures if a woman of child-bearing potential
References
Publications (0)
Data not yet available
No reference posted for this study.